A detailed history of Mercer Global Advisors Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Mercer Global Advisors Inc holds 10,787 shares of CRSP stock, worth $481,315. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,787
Previous 10,340 4.32%
Holding current value
$481,315
Previous $705,000 17.45%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$51.17 - $68.18 $22,872 - $30,476
447 Added 4.32%
10,787 $582,000
Q1 2024

May 15, 2024

SELL
$60.67 - $89.12 $42,226 - $62,027
-696 Reduced 6.31%
10,340 $705,000
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $1,969 - $3,681
51 Added 0.46%
11,036 $691,000
Q3 2023

Nov 13, 2023

BUY
$45.39 - $59.0 $17,929 - $23,305
395 Added 3.73%
10,985 $499,000
Q2 2023

Aug 14, 2023

SELL
$43.47 - $67.77 $90,721 - $141,435
-2,087 Reduced 16.46%
10,590 $594,000
Q1 2023

May 15, 2023

BUY
$41.0 - $56.12 $12,587 - $17,228
307 Added 2.48%
12,677 $573,000
Q4 2022

Feb 08, 2023

BUY
$39.19 - $65.67 $5,369 - $8,996
137 Added 1.12%
12,370 $503,000
Q3 2022

Nov 15, 2022

SELL
$61.1 - $83.78 $56,212 - $77,077
-920 Reduced 6.99%
12,233 $799,000
Q2 2022

Aug 10, 2022

SELL
$43.23 - $73.83 $10,159 - $17,350
-235 Reduced 1.76%
13,153 $800,000
Q1 2022

May 10, 2022

BUY
$53.19 - $79.24 $452,061 - $673,460
8,499 Added 173.84%
13,388 $840,000
Q4 2021

Feb 04, 2022

BUY
$70.09 - $111.29 $50,044 - $79,461
714 Added 17.1%
4,889 $370,000
Q3 2021

Nov 10, 2021

BUY
$110.2 - $156.64 $94,221 - $133,927
855 Added 25.75%
4,175 $467,000
Q2 2021

Aug 10, 2021

BUY
$100.84 - $161.89 $37,512 - $60,223
372 Added 12.62%
3,320 $537,000
Q1 2021

May 11, 2021

BUY
$110.72 - $210.04 $42,405 - $80,445
383 Added 14.93%
2,948 $359,000
Q4 2020

Feb 12, 2021

BUY
$79.67 - $173.23 $204,353 - $444,334
2,565 New
2,565 $393,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.48B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Mercer Global Advisors Inc Portfolio

Follow Mercer Global Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.